Transcenta is a global biotherapeutics company that specializes in the discovery, research, development, and manufacturing of antibody-based biotherapeutics. With a strong commitment to innovation, Transcenta integrates cutting-edge technology to deliver differentiated and affordable biologics to patients in need. With a presence in China and the United States, Transcenta has established a global footprint.

They have Headquarters, Discovery, Clinical, and Translational Research Centers in Suzhou and a Process and Product Development Center and Manufacturing Facility in Hangzhou. Additionally, Clinical Development Centers can be found in Beijing, Shanghai, Guangzhou, and Princeton. Transcenta is currently focused on developing thirteen therapeutic antibody molecules for various indications, including oncology and targeted non-oncology areas such as bone and kidney disorders.

Their pipeline includes core products like Osemitamab (TST001), TST002, and TST003. The company is committed to sustainability and adopts green and low-carbon practices in their operations, striving for the harmonious coexistence of economic development and environmental protection. Transcenta also places great emphasis on talent development and creating a positive work environment.

Through their dedication to scientific excellence, innovation, and patient-centricity, Transcenta aims to provide better and more affordable innovative treatments for patients worldwide